Mei-Hua Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mei-Hua Dong has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Jie-Lin Wang1 shared publication
- Jing Li
Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University
1 shared publication Jing Liu
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Department of Allergy and Clinical Immunology, The First Affiliated Hospital of Guangzhou Medical University , 151 Yanjiangxi Rd, Guangzhou, Guangdong 510120
1 shared publication- Ping-An Zhang
National Clinical Research Center for Respiratory Disease The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
1 shared publication - Ren-Ke Mo
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Department of Allergy and Clinical Immunology, The First Affiliated Hospital of Guangzhou Medical University , 151 Yanjiangxi Rd, Guangzhou, Guangdong 510120
1 shared publication - Rundong Qin
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Department of Allergy and Clinical Immunology, The First Affiliated Hospital of Guangzhou Medical University, 151, Yanjiangxi Rd, Guangzhou, Guangdong, 510120, China
1 shared publication
Latest Publications
- Open Access
- 1 March 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (2)
A causal glycerophospholipid–IL-18R1–CD9 axis connects lipid metabolism and T-cell activation in atopic dermatitis
Atopic dermatitis (AD) involves complex metabolic–immune dysregulation, but the molecular links remain unclear. This study integrates a multilevel analytical framework to systematically investigate the metabolic–immune crosstalk in AD. Using linkage disequilibrium score regression and a two-step Mendelian randomization approach, we established genetic correlations and inferred causal relationships between plasma metabolites and inflammatory proteins, identifying 1-palmitoyl-2-arachidonoyl-GPC (PA-GPC) as a protective metabolite that exerts its effect primarily through downregulation of interleukin-18 receptor 1 (IL-18R1). Integration of single-cell transcriptomic data further revealed elevated IL-18R1 expression in T cells within the AD microenvironment and enabled stratification of T cells based on PA-GPC–associated metabolic activity, identifying 33 differentially expressed genes. Subsequent least absolute shrinkage and selection operator (LASSO) regression, combined with machine learning models and SHapley Additive exPlanations analysis, consistently prioritized CD9 as a key regulator. Functional validation showed that PA-GPC attenuates tumor necrosis factor-alpha (TNF-α)/interferon-gamma (IFN-γ)–induced inflammatory responses in human immortalized keratinocyte (HaCaT) cells and suppresses Th2 cytokine production in T cells. IL-18R1 knockdown reduced CD9 expression and Th2 cytokine production in T cells, whereas CD9 knockdown did not affect IL-18R1 expression, indicating that IL-18R1 acts upstream of CD9. Moreover, CD9 knockdown impaired T-cell viability, activation, and Th2 cytokine production. Collectively, these findings characterize metabolic–immune crosstalk in AD and identify a PA-GPC–IL-18R1–CD9 regulatory axis with potential therapeutic implications.
- 1 March 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (2)
Open AccessA causal glycerophospholipid–IL-18R1–CD9 axis connects lipid metabolism and T-cell activation in atopic dermatitis
Atopic dermatitis (AD) involves complex metabolic–immune dysregulation, but the molecular links remain unclear. This study integrates a multilevel analytical framework to systematically investigate the metabolic–immune crosstalk in AD. Using linkage disequilibrium score regression and a two-step Mendelian randomization approach, we established genetic correlations and inferred causal relationships between plasma metabolites and inflammatory proteins, identifying 1-palmitoyl-2-arachidonoyl-GPC (PA-GPC) as a protective metabolite that exerts its effect primarily through downregulation of interleukin-18 receptor 1 (IL-18R1). Integration of single-cell transcriptomic data further revealed elevated IL-18R1 expression in T cells within the AD microenvironment and enabled stratification of T cells based on PA-GPC–associated metabolic activity, identifying 33 differentially expressed genes. Subsequent least absolute shrinkage and selection operator (LASSO) regression, combined with machine learning models and SHapley Additive exPlanations analysis, consistently prioritized CD9 as a key regulator. Functional validation showed that PA-GPC attenuates tumor necrosis factor-alpha (TNF-α)/interferon-gamma (IFN-γ)–induced inflammatory responses in human immortalized keratinocyte (HaCaT) cells and suppresses Th2 cytokine production in T cells. IL-18R1 knockdown reduced CD9 expression and Th2 cytokine production in T cells, whereas CD9 knockdown did not affect IL-18R1 expression, indicating that IL-18R1 acts upstream of CD9. Moreover, CD9 knockdown impaired T-cell viability, activation, and Th2 cytokine production. Collectively, these findings characterize metabolic–immune crosstalk in AD and identify a PA-GPC–IL-18R1–CD9 regulatory axis with potential therapeutic implications.